Expert Insights on COVID-19 Prophylaxis in Patients With Multiple Sclerosis and Related Disorders

Target Audience

Neurologists, nurse practitioners, PAs, nurses, pharmacists, and other members of the health care team caring for patients with MS.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

• Describe the rationale for the use of monoclonal antibodies for COVID-19 pre-exposure prophylaxis in patients with MS
• Review monoclonal antibodies for COVID-19 pre-exposure prophylaxis used with past FDA Emergency Use Authorization
• Discuss ongoing trials of monoclonal antibodies being studied for pre-exposure prophylaxis of COVID-19 in immunocompromised patients
• Identify patients with MS who may benefit from monoclonal antibodies for COVID-19 pre-exposure prophylaxis
• Review current guidance on pre-exposure prophylaxis of COVID-19 from regulatory agencies and professional medical organizations
• Employ team-based best practices for patient and care partner education on COVID-19 prevention, and implications on disease course and disease modification

Faculty

Program Chair
Avindra Nath, MD
National Institutes of Health
Clinical Director
National Institute of Neurological Disorders and Stroke
Bethesda, MD

Program Faculty
Jacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS
Professor, Vice Chair of Research
Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Neurology, University of Colorado, Anschutz Medical Campus
Aurora, CO

Anne H. Cross, MD, FAAN
Professor of Neurology
Manny and Rosalyn Rosenthal and Dr. John L. Trotter MS Center Chair in Neuroimmunology
Section Head of the Neuroimmunology/MS Section
Washington University School of Medicine
Saint Louis, MO

Jaime Imitola, MD, FAAN, FANA
Professor of Neurology, Vice-Chair of Research in Neurology
Chief, Division of Multiple Sclerosis and Neuroimmunology
Director, UConn Health Comprehensive MS Center
UConn School of Medicine
Farmington, CT

Carrie Sammarco, DrNP, FNP-C, MSCN
Nurse Practitioner
NYU Langone MS Comprehensive Care Center
New York, NY

Cameron R. Wolfe, MBBS (Hons), MPH, FIDSA, FAST
Professor of Medicine
Transplant Infectious Disease
Duke University Medical Center
Durham, NC

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.

Credit Designation

Physician
The CMSC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1.5 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
The CMSC designates this activity for a maximum of 1.5 NCPD credits (1.5 in the area of pharmacology).

Pharmacists
This knowledge-based activity, JA4008165-9999-24-009-H01-P, qualifies for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit.

All other health care professionals completing this course will be issued a statement of participation.

Contact Information

For questions about this activity, please contact Catamount Medical Education at [email protected].